The Industry’s Core Constraint Is No Longer Technology — It’s Execution
Author
Troy Bryenton is the VP Global Head of Clinical Technology and Strategy at Fortrea. Troy leads the IT team for the recently launched Fortrea Intelligent Technology™ product suite built to help sponsors and investigator sites run smarter, more connected clinical trials. He is a Senior Life Science Technology Executive with 20+ years of leadership experience, delivering innovative solutions that drive transformative organizational change. Troy has previous business technology leadership experience with Science 37, Syneos Health and IQVIA.
Clinical development is not lacking in innovation. Over the past decade, the industry has introduced advanced analytics, automation, artificial intelligence and digital platforms at pace. Many of these capabilities are mature, proven, and readily available. Yet the outcomes that matter most (cycle time, predictability, site and patient experience etc.) have improved far more slowly than the technologies themselves.
At the recent Fortrea Intelligent Technology (FIT) Summit (April 2026, Boston, MA), industry leaders converged on a shared conclusion: The constraint is not technological capability. The constraint is execution.
Too often, innovation enters the clinical environment as a pilot rather than an operating principle. Promising tools are tested in isolation, disconnected from core workflows, governance models and decision structures. Others are deployed as point solutions that add complexity rather than removing it. In these conditions, even sophisticated technology struggles to scale, creating fragmentation instead of momentum and value that is episodic rather than reliable.
This exposes a deeper challenge: technology alone does not transform execution. Transformation demands an operating model designed to embed intelligence directly into how trials are planned, run and governed. That is the shift that is now taking place across clinical development.
Effective execution begins with embedded intelligence technology that operates within workflows rather than alongside them. When insights are surfaced where decisions are made, rather than delivered as downstream reports or optional tools, adoption follows naturally and impact becomes repeatable.
It also depends on trusted data foundations. Intelligence is only as strong as the context, provenance and integrity of the data that underpins it. Without this, advanced analytics and AI remain constrained to narrow use cases, unable to support confident, real‑time decision‑making across the trial lifecycle.
Equally important is the ability to scale with intent. Moving beyond pilot programs requires disciplined governance, clear ownership, and platforms designed for reuse and extension, not one-off deployments. Execution improves when experimentation is structured, learning is retained, and successful capabilities are industrialized rather than repeatedly reinvented.
Finally, clinical development remains, and must remain, a human-led endeavor. Technology should remove friction, automate repetition and surface insight, allowing clinical and operational specialists to focus on judgement, oversight and patient impact. Execution improves when humans are elevated, not displaced.
The next phase of clinical development will not be defined by who introduces the newest technology first. It will be defined by who executes with consistency, confidence and scale, aligning people, process and technology around outcomes that matter.
Innovation is no longer the limiting factor. Execution is, and with the right foundations, it is finally within reach.
Learn more about Fortrea’s approach by messaging FIT@fortrea.com or visiting Fortrea Intelligent Technology.